Loading company…
Shanghai biopharma developing novel treatments for central nervous system disorders, founded in 2021.
Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd., trading as Synphatec, develops novel treatments for central nervous system disorders, including preclinical and early clinical programs for depression and Alzheimer's disease. Founded in 2021 and based in Shanghai, China, it raised over USD 50 million in Series A funding in September 2026, led by Decheng Capital, with participation from Huatai Zijin Investment, China Merchants Venture Investment Management, 5Y Capital, Shunwei Capital and Qianju Capital. The funding will advance clinical development of SP-101 and SP-201.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in